Clinical Trial

Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis

Study acronym: HP-THERAPY-TRI
Completed Phase 4
View on ClinicalTrials.gov →
Summary
This randomized controlled trial is designed to compare the efficacy of standard triple therapy versus bismuth-based quadruple therapy for the eradication of Helicobacter pylori-induced gastritis. The study is being conducted at Shahida Islam Medical College, Lodhran, Pakistan. Adult patients with confirmed H. pylori infection are randomly allocated to receive either a 14-day triple therapy regimen or a 14-day bismuth-based quadruple therapy regimen. Eradication of H. pylori is assessed six weeks after completion of treatment using stool antigen testing. The primary outcome measure is the proportion of patients achieving successful eradication of H. pylori.
Trial Details
NCT Number NCT07312721
Lead Sponsor Azfar Farogh
Conditions Helicobacter Pylori Infection, Chronic Gastritis, Peptic Ulcer Disease
Enrollment 752 participants
Start Date 2024-01-05
Primary Completion 2024-12-30 (estimated)
Study Completion 2024-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-31